Health Economics›Chronic lymphocytic leukemia›First-line therapy randomized data

First-line therapy randomized data

Chronic lymphocytic leukemia · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Chlorambucil and Ofatumumab Variant #01	—	R 1 179 792	28d	22.4 mo	—	25	R 29 494 801 PFS proxy	1
Ibrutinib and Rituximab Variant #05	—	R 391 307	56d	—	—	—	—	3
Bendamustine and Rituximab (BR) and Ibrutinib Variant #02	—	R 349 542	56d	—	—	—	—	2
Ibrutinib, Venetoclax, Obinutuzumab Variant #01	—	R 320 204	28d	—	—	—	—	2
Ibrutinib and Venetoclax Variant #01	—	R 250 300	28d	—	—	—	—	9
Venetoclax and Obinutuzumab Variant #01	—	R 240 071	28d	76.2 mo	—	83	R 19 925 934 PFS proxy	6
Ibrutinib and Obinutuzumab Variant #01	—	R 175 528	28d	—	—	—	—	1
Acalabrutinib and Obinutuzumab Variant #01	—	R 174 612	28d	—	—	—	—	3
Obinutuzumab monotherapy Variant #03	—	R 166 941	21d	—	—	—	—	—
Alemtuzumab monotherapy Variant #01	—	R 132 218	7d	15.0 mo	—	66	R 8 726 355 PFS proxy	—
Fludarabine and Alemtuzumab Variant #02	—	R 116 300	28d	23.7 mo	—	26	R 3 023 811 PFS proxy	2
Chlorambucil and Obinutuzumab (GClb) Variant #01	—	R 96 236	28d	27.8 mo	—	31	R 2 983 309 PFS proxy	10
FCA Variant #01	—	R 84 405	28d	—	—	—	—	1
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	106.8 mo	—	117	R 9 375 543 PFS proxy	10
Acalabrutinib monotherapy Variant #01	—	R 79 217	28d	—	—	—	—	2
FCR Variant #09	—	R 70 417	28d	57.6 mo	—	63	R 4 436 266 PFS proxy	9
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	—	—	2
Cladribine monotherapy Variant #01	—	R 59 905	5d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	43.2 mo	—	47	R 1 917 927 PFS proxy	6
Chlorambucil and Rituximab (RClb) Variant #03	—	R 28 365	28d	23.1 mo	—	26	R 737 482 PFS proxy	2
Cladribine and Cyclophosphamide (CC) Variant #01	—	R 20 110	28d	—	—	—	—	—
FCR (SC Rituximab) Variant #01 Partial	—	R 18 989	28d	—	—	—	—	—
Bendamustine monotherapy Variant #01	—	R 5 419	—	19.1 mo	—	—	—	—
Watchful waiting Partial	—	—	—	12.9 mo	—	—	—	—

24 of 24 regimens shown